Clinical Notice:
This protocol framework is intended for licensed healthcare professionals. It assumes appropriate clinical training, sterile technique, and regulatory compliance. It is not intended for patient-directed use.
Overview
A staged adjunctive peptide protocol designed to support post-procedural hair regeneration when used alongside PRP, exosome therapy, and red-light photobiomodulation. This framework defines screening requirements, stepwise selection logic, dosing and titration parameters, objective response thresholds, safety monitoring (including copper surveillance for GHK-Cu), and clinical decision checkpoints to guide escalation, maintenance, or discontinuation.
Clinical Scope
| Adjunct to PRP-based hair restoration protocols |
| Adjunct to exosome-based scalp therapy protocols |
| Adjunct to red-light therapy / photobiomodulation protocols |
| Patients demonstrating delayed response or suboptimal recovery trajectory |
Pre-Treatment Screening
Required Laboratories:
| Serum copper and ceruloplasmin (GHK-Cu baseline safety) |
| CBC |
| CMP |
Exclusions:
| Active malignancy |
| Pregnancy or nursing |
| Uncontrolled autoimmune disease |
| Wilson’s disease |
Consent:
| Document off-label use and limited long-term safety data |
| Document baseline status and objective monitoring plan |
Peptide Selection Strategy
Standard initiation begins with GHK-Cu plus BPC-157 for synergistic repair and regenerative signaling support. TB-500 is reserved for poor responders only, based on objective thresholds.
Selection Logic
| GHK-Cu + BPC-157: Standard protocol for most cases (synergistic healing and regeneration) |
| GHK-Cu alone: Low-complexity cases, cost constraints, or contraindication to BPC-157 |
| Add TB-500: Only after Weeks 6–8 if objective improvement is <15% |
Peptide Profiles and Operational Parameters
1) GHK-Cu (First-Line)
Clinical Synergy: Supports VEGF and TGF-β signaling, potentiates red-light mitochondrial effects, reduces inflammation while supporting angiogenesis.
Topical (Preferred Initial)
| Formulation: 0.5% to 1% pharmaceutical-grade cream |
| Application: Pea-sized amount per treatment zone |
| Timing: Evening application; massage 2–3 minutes |
| Photobiomodulation sequencing: Wait 45–60 minutes, then perform red-light session |
Titration
| Start at 0.5% |
| Increase to 1% at Week 4–6 if objective improvement is <15% |
Injectable (Add if topical insufficient by Week 6)
| Dose: 0.5–1.0 mg subcutaneous |
| Frequency: 3x weekly (e.g., Mon/Wed/Fri) |
| Technique: 0.1 mL per site; 4–6 mm depth; rotate 8–10 mapped points |
Injectable Titration
| Start 0.5 mg |
| Increase to 1.0 mg if tolerated and response remains <15% |
Mathematical Calculation Tool
The calculator below allows mathematical concentration and volume calculations using variable vial strengths and reconstitution volumes. This tool is provided strictly for arithmetic reference.
Peptide Reconstitution Calculator
For Educational & Professional Reference Only
Clinical Disclaimer
This protocol framework is provided for educational and informational purposes for licensed healthcare professionals. The statements and therapies outlined have not been evaluated by the Food and Drug Administration. These products and protocols are not intended to diagnose, treat, cure, or prevent any disease. Patient-specific medical history, concurrent medications, contraindications, and regulatory considerations must be evaluated prior to initiation. Clinical judgment and appropriate supervision are required.